Institute of Medical Sciences, University of Toronto, Toronto, Canada.
Toronto Centre for Liver Disease, Toronto General Hospital, Toronto, Canada.
Hum Vaccin Immunother. 2021 Jul 3;17(7):2293-2297. doi: 10.1080/21645515.2020.1861878. Epub 2020 Dec 30.
Viral infection typically originates from a limited number of virions known as transmitted/founder (T/F) viruses. Studies of cross-species transmission, and intra-species transmission of antigenically variable viruses, indicates T/F variants may express distinct, transmissibility enhancing phenotypes. However, with evidence that transmissibility is associated with not only intrinsic virological features, such as virion composition, but also extrinsic factors, such as viral population structure, the challenge of resolving T/F signatures that can be targeted by rational vaccine or antiviral design is substantial. Nonetheless, failure to develop vaccines for antigenically variable viruses, such as HIV/HCV, and the ongoing risk of cross-species transmission with pandemic potential, recommends development of T/F targeting vaccines. In this commentary, the T/F phenomena is introduced, explored in both the classical (HIV) and non-canonical (coronaviruses) instances, and discussed in relation to rational and preemptive vaccine design.
病毒感染通常起源于少数被称为传播/创始(T/F)病毒的病毒粒子。对种间传播和抗原可变病毒的种内传播的研究表明,T/F 变体可能表现出不同的、增强传染性的表型。然而,有证据表明,传染性不仅与病毒学特征(如病毒粒子组成)等内在因素有关,还与病毒群体结构等外在因素有关,因此解决可通过合理疫苗或抗病毒设计靶向的 T/F 特征具有相当大的挑战性。尽管如此,对于抗原可变病毒(如 HIV/HCV)未能开发出疫苗,以及具有大流行潜力的种间传播的持续风险,仍推荐开发针对 T/F 的疫苗。在这篇评论中,介绍了 T/F 现象,分别在经典(HIV)和非规范(冠状病毒)实例中进行了探讨,并就合理和先发制人的疫苗设计进行了讨论。